Drug Database
AD

adalimumab (Mabura)

✓ Approved

Hetero Labs · TNF · 单克隆抗体

什么是 adalimumab?

adalimumab 是一种单克隆抗体,由Hetero Labs研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名Mabura
公司Hetero Labs
药物类别单克隆抗体, 抗体
分子靶点TNF
给药途径Injectable (Others), Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

adalimumab 作用于 1 个分子靶点:

TNFtumor necrosis factor (TNFA, TNF-alpha)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

adalimumab 针对 10 个适应症,涉及 4 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersHidradenitis✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

注册免费账户还可查看另外 5 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedThe Journal of clinical and aesthetic dermatology2026-11-17

Advancing Our Understanding of Hidradenitis Suppurativa: A Comprehensive Guide for Clinicians Designed to Improve Therapeutic Outcomes for Patients-Part 3.

Del Rosso James Q JQ, Lam Lauren L, Dasilva Diego Ruiz DR, Burshtein Joshua J et al.

Despite greater awareness of hidradenitis suppurativa (HS) as a well-defined, chronic inflammatory skin disorder that can flare unpredictably and be highly symptomatic, both patients and clinicians face challenges in facilitating care that is expedient, effective, reasonably safe, and accessible. Fortunately, since the approval of the injectable anti-tumor necrosis factor (TNF)-α agent, adalimumab, in 2015 by the United States Food and Drug Administration (FDA), treating HS inflammation that is not visible clinically but is occurring steadily and progressively below the surface of the skin has proven to be of extreme importance to patients, especially as related to long-term management. The mechanism of action (MOA) of properly selected biologic therapy inhibits both the inflammation associated with active primary HS skin lesions and the subsequent irreversible fibrotic and cicatricial dermal sequelae that form due to destructive changes occurring more deeply within inflamed HS lesions. Over the past decade, the ability to therapeutically and pharmacologically halt the progression of irreversible tissue destruction in HS has emerged, first with anti-TNF-α therapy and then later with anti-interleukin (IL)-17 therapies. In this third article of a 4-part series on HS, information on therapeutic management is expanded to include secukinumab and bimekizumab, both FDA-approved anti-IL-17 monoclonal antibodies for moderate-to-severe HS in adults. Additional topics covered in this article embrace other MOAs and cascades of inflammation that are believed to markedly contribute to HS pathophysiology and provide therapeutic benefit, including systemic Janus kinase inhibitors and glucagon-like peptide-1 receptor agonists. Ultimately, the goal of this 4-part article series is to provide a substantial scientific foundation on the disease state coupled with a practical, reasonably comprehensive, and clinically useful collection of source information that can serve as a valuable "guidance tool" to assist clinicians in managing HS. As stated in the first article of this series, multiple authors have separately contributed individual sections inclusive of supporting references. All authors were primarily responsible for their individual sections but also participated in the review and finalization of the complete series of articles. The order of the authors reflects the order of appearance of their primary sections in the 4-part article series.

PMID 43042353
阅读全文 →
PubMedScandinavian journal of gastroenterology2026-11-16

Endoscopic remission in Crohn's disease differs by location and is differentially influenced by disease duration.

Wong Emily C L ECL, Marshall John K JK, Ma Christopher C, Jairath Vipul V et al.

Endoscopic remission (ER) is a key therapeutic goal in Crohn's disease (CD), yet mucosal healing is less frequent in the ileum than in the colon. While longer disease duration reduces the likelihood of ER, whether this effect differs by location is unclear. We conducted a post hoc pooled analysis of individual patient data from four trials (EXTEND, VISIBLE-2, VERSIFY and SEAVUE) via Vivli protocol #10706. A total of 422 patients with baseline Simple Endoscopic Score for Crohn's Disease (SES-CD) >3 treated with adalimumab, vedolizumab or ustekinumab and with week-52 endoscopic data were included. Patients were categorized as ileal (n = 332) or colonic (n = 303). ER was defined as SES-CD = 0 or <3. Associations between disease duration (<1, <2, <3 years vs. longer) and ER were analyzed using chi-square tests and logistic regression adjusted for treatment. Shorter disease duration was associated with higher ER rates overall (SES-CD <3: 35.9% vs. 24.1%, p = 0.018; adjusted OR [aOR] 0.57, 95% CI: 0.32-0.99, p = 0.049). In ileal disease, shorter duration modestly increased ER (31.8% vs. 21.3%, p = 0.048) but was not significant after adjustment (aOR 0.68, 95% CI: 0.39-1.19, p = 0.18). In colonic disease, the association was stronger (SES-CD <3: 39.5% vs. 18.9%, p < 0.001; aOR 0.44, 95% CI: 0.24-0.78, p = 0.005). Shorter disease duration predicts higher ER rates, particularly in colonic CD. These findings suggest earlier initiation of biologic therapy may improve healing in colonic disease, whereas ileal healing may be limited by location-specific factors.

PMID 43037208
阅读全文 →
PubMedSage open chronic disease2026-11-15

Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives.

Carugno Andrea A, Bighetti Stefano S, Fratton Zeno Z, Bettolini Luca L et al.

Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory dermatosis affecting approximately 1% of the population, with a female predominance and substantial psychosocial burden. Clinically, it presents with painful nodules, abscesses, and draining tunnels that often progress to fibrosis and long-term disability. Pathogenesis is multifactorial, encompassing follicular occlusion and rupture, dysbiosis, neutrophil-rich inflammation, and cytokine networks driven by tumor necrosis factor-alpha and interleukin-17 (IL-17), and despite advances, major challenges persist, including phenotypic heterogeneity, diagnostic delays, and the limited durability of monotherapies. This narrative review critically synthesizes evidence on combination strategies in HS following a systematic search of PubMed, Embase, and Cochrane (2009-July 2025), including randomized and nonrandomized trials, cohorts, and case series (⩾10 patients) that evaluated multimodal approaches (antibiotics plus biologics, biologics within surgical pathways, small molecules in combination, laser/light-based therapies, and structured wound care). Outcomes of interest included Hidradenitis Suppurativa Clinical Response, International Hidradenitis Suppurativa Severity Score System (IHS4)/IHS4-55, tunnel resolution, patient-reported measures (Dermatology Life Quality Index), flare frequency, and safety; qualitative synthesis was performed according to Scale for the Assessment of Narrative Review Articles criteria. Antibiotics remain valuable for induction or bridging: clindamycin-rifampicin and multidrug regimens (rifampin-moxifloxacin-metronidazole, ertapenem) yield meaningful but time-limited benefit, optimally used as preparatory steps toward long-term interventions. Biologics form the backbone of durable disease control (adalimumab, secukinumab, bimekizumab), with enhanced outcomes when initiated alongside antibiotics or integrated perioperatively with surgery for tunnel eradication. Among small molecules, Janus kinase inhibitors (e.g., upadacitinib) show promising efficacy; apremilast and IL-36 blockade are exploratory options; sirolimus and conventional immunosuppressants retain niche utility in syndromic or refractory phenotypes. Adjunctive measures, including laser/light therapies, structured wound care, metabolic interventions (notably glucagon-like peptide-1 receptor agonists), smoking cessation, and psychological support, further consolidate disease control, while multidisciplinary care models optimize sequencing, comorbidity management, and recurrence reduction. In conclusion, combination therapy has emerged as the organizing principle of modern HS management: integrating antibiotic induction, biologics for long-term modification, targeted surgery, and adjunctive measures enables deeper and more durable responses. Future priorities include treat-to-target strategies, biomarker-guided selection, antimicrobial stewardship, and pragmatic real-world evaluations to advance toward near-clearance in a broader patient population.

PMID 43034520
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Uveitis in Patients with Inflammatory Bowel Disease: Pharmacovigilance Signal Detection and Nationwide Claims-Based Evaluation.

Hwang Sunjin S, Kim Jiyeong J, Hong Eun Hee EH, Chung Jee-Eun JE et al.

Background/Objectives: To evaluate uveitis risk among biologic users with IBD using signal detection and nationwide outcome data. Methods: We performed a disproportionality analysis of the FDA Adverse Event Reporting System and a retrospective nationwide cohort study of 7862 Korean patients with IBD who initiated adalimumab, vedolizumab, or ustekinumab between 2015 and 2024. Incident uveitis, identified by diagnostic codes, was compared before and after biologic initiation in exploratory analyses to calculate incidence rate ratios, with post-exposure divided into 0-90 and beyond 90 days; cumulative incidence and multivariable Cox regression were also assessed. Post-switch uveitis risk was compared between patients switching from adalimumab to vedolizumab or ustekinumab. Results: Disproportionality analysis identified positive signals for adalimumab (reporting odds ratio, 4.97) and vedolizumab (2.80), but not ustekinumab (0.63). No statistically significant increase in uveitis incidence was observed after biologic initiation in the cohort. No events occurred within 90 days of vedolizumab or ustekinumab initiation; beyond 90 days, incidence rate ratios were 1.3 (95% confidence interval [CI], 0.6-2.9) and 0.6 (95% CI, 0.2-1.7). Adjusted cumulative incidence at the end of follow-up was 1.1%, 0.6%, and 0.2% for adalimumab, vedolizumab, and ustekinumab, with no significant differences on Cox regression. Post-switch risk was similar between vedolizumab and ustekinumab (hazard ratio, 0.88; 95% CI, 0.14-5.58). Conclusions: Pharmacovigilance signals for adalimumab and vedolizumab were not reproduced in a nationwide cohort, in which no statistically significant difference in uveitis risk was detected among the three biologics. Given the small number of events and potential selection bias, these descriptive findings do not exclude clinically important differences between treatments.

PMID 43030435
阅读全文 →
PubMedZeitschrift fur Gastroenterologie2026-11-14

[Adjunctive enteral nutrition in Crohn's disease during biologic therapy: More than a supportive measure? A narrative review].

Peters Sarah S, Tessmer Lea L, Dignass Axel A, Stein Jürgen J

This narrative review aimed to critically evaluate evidence for combining enteral nutrition (EN) with biologic therapy in adults with Crohn's disease (CD). PubMed, Embase and the Cochrane Library were searched on EN combined with biologics, incl. infliximab, adalimumab, vedolizumab, and ustekinumab. Studies published from 01/2018-06/2026 and current clinical guidelines were considered. The evidence was evaluated regarding clinical effectiveness and methodological limitations. Current evidence suggests that adding enteral nutrition to biologic therapy may relatively increase clinical and endoscopic remission rates by up to 50 % compared with biologic monotherapy. The potential benefit may be due to enhanced mucosal healing, alterations in the intestinal microbiome, and improved pharmacokinetics. Higher rates of transmural healing and lower relapse, treatment escalation, and surgery rates have also been reported. While exclusive EN has a broader evidence base, partial EN may offer advantages in clinical practice because of its greater feasibility and acceptability. Evidence is limited by selection bias, heterogeneous treatment protocols and lack of blinding. Combining EN with biologics is a promising therapeutic approach for adults with CD. Prospective RCTs are needed to establish efficacy, safety and optimal use of exclusive and partial EN.

PMID 43025458
阅读全文 →
PubMedOcular immunology and inflammation2026-11-13

Incidence and Prevalence of Retinal Vasculitis and Associated Autoimmune Comorbidities, Ocular Complications, and Treatment Patterns.

Rama Taulant T, Berkenstock Meghan M

To investigate the incidence, prevalence, associated conditions and therapeutic modalities of retinal vasculitis (RV). Subjects diagnosed with RV in the TriNetX database between 2014 and 2024 were identified using the ICD-10 codes, excluding those with AIDS or HIV. The primary outcomes were the incidence and prevalence (annual and 10‑year cumulative). Demographic data, autoimmune comorbidities, immunosuppressive medication, ocular complications, and local ocular therapies at the time of or following diagnosis were collected for secondary analyses. From 114 907 642 subjects, 5342 cases of RV were identified. Demographic data included: 63.42% (N = 3387) women, 59.04% (N = 3154) White, 73.61% (N = 3932) Non-Hispanic or Latino and a mean age of 55 years (range 2-90). The most common autoimmune comorbidities were rheumatoid arthritis (3.88%, N = 199), sarcoidosis (3.48%, N = 179) and systemic lupus erythematosus (2.98%, N = 149). The most used systemic immunosuppressive medications were methotrexate (10.60%, N = 535), mycophenolate mofetil (9.88%, N = 502) and adalimumab (8.68%, N = 456). The most prevalent ocular complication was cystoid macular edema (21.06%, N = 956) and intravitreal injections (10.95%, N = 531) were the most frequently used procedure. Among the intravitreal agents, triamcinolone (7.07%, N = 362) was the most administered. Between 2014 and 2024, the incidence increased from 0.99 to 1.35 per 100 000 persons and the prevalence from 3.75 to 9.47 per 100 000 persons. The rising incidence and prevalence of retinal vasculitis appear to be multifactorial, highlighting the need for interdisciplinary care, close monitoring and early intervention.

PMID 43024624
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多adalimumab